Lisa Cibik, MD
Ophthalmology · West Mifflin, PANPI 1477559854
Payments from drug & device makers
Across 327 payments — averaging $101.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$10K
- Bausch Health US, LLC$8K
- Beaver-visitec International, Inc.$7K
- Kala Pharmaceuticals, Inc.$4K
- Sun Pharmaceutical Industries Inc.$1K
- Novartis$1000
- plus $3K from 20 others
Across 1 payment — averaging $28,160 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beaver-visitec International, Inc.$28K
What the payments were for
- Consulting fees$11,37553%
- Speaking & faculty fees$3,18515%
- Food & beverage$6,91532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 66 | $9,750 |
| Bausch Health US, LLC | 3 | $8,154 |
| Beaver-visitec International, Inc. | 1 | $6,720 |
| Kala Pharmaceuticals, Inc. | 9 | $3,591 |
| Sun Pharmaceutical Industries Inc. | 56 | $1,225 |
| Novartis | 67 | $1,000 |
| Bausch & Lomb Americas Inc. | 41 | $683 |
| NEW World Medical,inc. | 10 | $250 |
| Ocular Therapeutix, Inc. | 10 | $215 |
| Tarsus Pharmaceuticals, Inc. | 8 | $214 |
| Glaukos Corporation | 4 | $196 |
| AbbVie(2 entities) | 5 | $128 |
| Harrow Eye, LLC | 5 | $128 |
| Oyster Point Pharma, Inc. | 6 | $124 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $122 |
| Regeneron Healthcare Solutions, Inc. | 3 | $92 |
| Thea Pharma Inc. | 5 | $88 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $84 |
| Aerie Pharmaceuticals, Inc. | 5 | $83 |
| Biotissue Holdings Inc. | 3 | $64 |
| Sight Sciences, Inc. | 2 | $45 |
| Apellis Pharmaceuticals, Inc. | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Amgen | 1 | $24 |
| Lumibird Medical Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof IQ PanOptix$3,424
- ORA$3,185
- PanOptix$1,470
- CEQUA$239
- CE-marked KXLA system$138
- Kahook Dual Blade$137
- Streamline Surgical System$137
- Ahmed Glaucoma Valve$137
- ReSTOR$137
- Clareon$136
- XELPROS$124
- AcrySof$122
- Clareon PanOptix Pro$121
How this compares
$33,079 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 390 | $480,370 |
| RestasisCyclosporine | 248 | $246,307 |
| LumiganBimatoprost | 414 | $184,451 |
| Cyclosporine | 293 | $177,491 |
| RocklatanNetarsudil Mesylat/Latanoprost | 103 | $50,670 |
| ProlensaBromfenac Sodium | 124 | $43,483 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 219 | $42,291 |
| CequaCyclosporine | 35 | $30,807 |
| CombiganBrimonidine Tartrate/Timolol | 131 | $30,763 |
| MieboPerfluorohexyloctane/Pf | 35 | $28,384 |
| Bromfenac Sodium | 253 | $25,995 |
| Alphagan PBrimonidine Tartrate | 78 | $25,612 |
| VyzultaLatanoprostene Bunod | 58 | $24,972 |
| Brimonidine Tartrate | 380 | $22,904 |
| Travoprost | 79 | $18,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $683 | $533,727483 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P, Restasis Multidose | $128 | $498,143887 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $83 | $65,180140 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax, Loteprednol Etabonate, Besivance | $84 | $56,104166 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,225 | $30,80735 claims |
| NovartisIlevro | $1,000 | $15,09142 claims |
| AlconSimbrinza | $9,750 | $10,71949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in West Mifflin
- Brian JewartWest Mifflin$87K
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.